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Background: Adoptive T cell therapy represents an attractive modality for the treatment of patients with cancer.
Peripheral blood mononuclear cells have been used as a source of antigen specific T cells but the very low
frequency of T cells recognizing commonly expressed antigens such as NY-ESO-1 limit the applicability of this
approach to other solid tumors. To overcome this, we tested a strategy combining IL-21 modulation during
in vitro stimulation with first-in-class use of tetramer-guided cell sorting to generate NY-ESO-1 specific cytotoxic
T lymphocytes (CTL).
Methods: CTL generation was evaluated in 6 patients with NY-ESO-1 positive sarcomas, under clinical manufacturing
conditions and characterized for phenotypic and functional properties.
Results: Following in vitro stimulation, T cells stained with NY-ESO-1 tetramer were enriched from frequencies as low
as 0.4% to >90% after single pass through a clinical grade sorter. NY-ESO-1 specific T cells were generated from all 6
patients. The final products expanded on average 1200-fold to a total of 36 billion cells, were oligoclonal and contained
67-97% CD8+, tetramer+ T cells with a memory phenotype that recognized endogenous NY-ESO-1.
Conclusion: This study represents the first series using tetramer-guided cell sorting to generate T cells for adoptive
therapy. This approach, when used to target more broadly expressed tumor antigens such as WT-1 and additional
Cancer-Testis antigens will enhance the scope and feasibility of adoptive T cell therapy.
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The use of antigen-specific T cells for adoptive immuno-
therapy of patients with advanced cancers is emerging as
a promising treatment modality [1-3]. Recent trials using
genetic modification of T cells to introduce chimeric
antigen receptors (CAR’s) or T cell receptors (TCR’s)
and redirect their target specificity to tumor cells can be
remarkably effective in reducing tumor burden and pro-
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unless otherwise stated.some solid tumors [4-10]. However, the regulatory and
logistical hurdles of gene transfer can be prohibitive and
issues such as receptor mispairing (for TCRs), target anti-
gen affinity, and serious, occasionally life-threatening,
even lethal on-target toxicities remain to be fully ad-
dressed [11,12]. Although once fully characterized, these
genetically modified approaches may be quite expedient,
they first require a priori possession of the relevant recep-
tor sequence from the cognate antibody for a CAR or a T
cell clone for a TCR as well as rigorous validation, all of
which limit the flexibility of this approach and incur sig-
nificant obstacles to bringing a cell product to the clinic.
An alternative approach, involves the isolation of cir-
culating endogenous antigen-specific T cells from theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and ex vivo expansion for adoptive transfer. Although
these tumor-reactive T cells can be present at very low fre-
quency, the feasibility of isolating and expanding endogen-
ous antigen-specific CTL from the peripheral blood of
patients for adoptive therapy has been demonstrated in
trials targeting melanocyte antigens such as gp100 and
MART-1 in melanoma, with intriguing evidence of clinical
efficacy [2,13]. The endogenous frequency of CTL target-
ing melanocyte antigens such as MART-1 is particularly
high (up to 1%) enabling facile generation of MART-1-
specific T cells using conventional approaches [2,13,14].
However, for more commonly expressed tumor antigens
such as WT-1, MAGE family antigens and NY-ESO-1, the
generation of antigen-specific cytotoxic T lymphocytes
(CTL) has been labor and resource-intensive and largely
unsuccessful on a routine basis due to their relatively rare
endogenous precursor frequencies (<1:10,000).
With the exception of MART-1 and some tumor-
associated viral antigens, generation of antigen-specific
T cells using a conventional approach involving repeated
cycles of autologous PBMC stimulation using peptide-
pulsed dendritic cells (DC’s) often fails to enrich low fre-
quency tumor-reactive CTL to numbers sufficient for
expansion and adoptive transfer.
To address this issue, we previously discovered that
the addition of IL-21 during the initial priming period
could increase the total number of antigen-specific CD8
T cells by >20-fold and, at the clonal level, enrich for a
population of high-affinity CD8 T cells with sustained
elevation of CD28 levels and a helper-independent pheno-
type. This enrichment can be further enhanced by deple-
tion of CD25+ Treg cells from the responder PBMC prior
to in vitro stimulation [15-17], leading to a synergistic in-
crease in the yield of antigen-specific CTL to 2-300 fold
greater than those cultures that were CD25 replete and
not exposed to IL-21 [18,19].
Therefore, to broaden the scope of patients eligible for
adoptive therapy and the tumors that can be treated, we
chose to target a prototypic cancer-testis antigen, NY-
ESO-1, expressed by several solid tumor malignancies, in-
cluding breast cancer, lung cancer, melanoma, sarcoma
and ovarian cancer. We developed a strategy where NY-
ESO-1 specific T cells were first enriched through in vitro
stimulation of CD25 depleted PBMC [17] with peptide
pulsed dendritic cells in the presence of IL-21, followed by
tetramer guided cell sorting to isolate and expand autolo-
gous NY-ESO-1-specific CTL from the peripheral blood
of patients with sarcoma under clinically compliant manu-
facturing conditions.
To determine whether highly avid, oligoclonal NY-ESO-1
specific CD8+ T cells recognizing NY-ESO-1 positive tumor
cell lines could be consistently isolated from patients who
might benefit from NY-ESO-1 targeted therapy, we focusedon patients with synovial sarcoma (SS) and myxoid/round
cell liposarcoma (MRCL) because these tumors homoge-
nously express NY-ESO-1, often with high intensity [20,21].
We successfully isolated NY-ESO-1 specific T cells from
6 of 6, NY-ESO-1 expressing sarcoma patients using a
clinical grade INFLUX cell sorter (Becton Dickson) and
propagated these highly enriched populations to sufficient
numbers for adoptive immunotherapy.
Results
Patient characteristics and leukapheresis yield
Isolation and expansion of NY-ESO-1 specific T cells
from leukapheresis products was attempted in six pa-
tients with SS (n = 5) and MRCL (n = 1) that expressed
NY-ESO-1 in their diagnostic tumor biopsies (Table 1).
The median age of these patients was 44 (26-48), which
is older than the reported median age for SS patients
[22]. Prior to leukapheresis, two of the six patients had
received chemotherapy including doxorubicin and ifosfa-
mide (A/I). The remaining four patients underwent leu-
kapheresis before receiving chemotherapy. A range of
5 × 109 – 13.6 × 109 mononuclear cells was obtained by
leukapheresis from each of the six patients. The yield
did not correlate with prior chemotherapy, suggesting
that prior chemotherapy was not a significant barrier to
obtaining an adequate leukapheresis collection (Table 1).
We depleted CD25+ cells from an aliquot of 2 × 109 cells
to remove regulatory T cells prior to establishing T cell
cultures resulting in a 1-2 log reduction in CD25+ cells
(data not shown). The average yield after CD25 deple-
tion was 1.34 × 109 cells (range 0.99 to 1.56 × 109).
Production of clinical grade NY-ESO-1 specific T cells by
cell sorting
The strategy to isolate NY-ESO-1 specific T cells from
PBMC is illustrated in Figure 1. For patient #1, three 48
well plates were plated with T cells and peptide pulsed
DC’s. After two stimulations, each individual well was
stained with the NY-ESO-1 tetramer and analyzed by flow
cytometry. NY-ESO-1 tetramer positive CD8+ T cells were
not observed in the starting leukapheresis product (detec-
tion threshhold <0.01%, Figure 1A), however 3 of the 144
stimulated wells contained NY-ESO-1 tetramer positive T
cells at a frequency of >0.5% (Figure 1B). These three wells
were pooled and the tetramer binding T cells were sorted,
expanded initially in a T25 flask and subsequently in Life-
cell Bags in the CPF. The final product was >94% CD8+
and NY-ESO-1 tetramer positive and specifically lysed
T2 cells pulsed with NY-ESO-1157-165 peptide and the
NY-ESO-1 expressing melanoma cell line, MelA375
(see Figure 1C and D).
Similar to patient #1, none of the remaining 5 patients
had detectable NY-ESO-1 specific T cells by tetramer
staining of starting PBMC (data not shown). One or two









Patient 1 SS 47 None Soft tissue, lung, brain 7.11 0.99
Patient 2 MRCL 35 Rtx Bone, soft tissue, lung 6.9 1.44
Patient 3 SS 48 A/I, HD Ifos, Rtx Brain, lung 5.14 1.2
Patient 4 SS 46 A/I/Vincristine, Rtx/Ifos Lung 14 1.365
Patient 5 SS 26 None Lung, kidney, soft tissue 11.2 1.56
Patient 6 SS 42 None Recurrent, locally advanced axillary disease 13.76 1.46
Rtx - Radiation therapy; A/I - Adriamycin and Ifosfamide; Gem/tax - gemcitabine and docetaxel; Doxil - liposomal doxorubicin; A/I/DTIC - Adriamycin, Ifosfamide
and Decarbazine.
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with NY-ESO-1157-165 peptide pulsed DC’s. After two
stimulation cycles, at least three wells (range 3 to 7)
from each patient contained NY-ESO-1 tetramer positive
cells at a frequency of 0.01-8.05% (Table 2). Overall, the
average number of wells per patient that contained
NY-ESO-1 tetramer positive cells was 3.8 (out of total
of 48-144 wells) and the mean frequency of NY-ESO-1
tetramer positive cells in these wells was 1.67%. This con-
trasts with the robust response seen with MART-1 where
under similar culture conditions typically every well will
have >1% tetramer positive cells, and occasional wells will
exhibit a robust MART-1-specific response with >20%
tetramer positive cells (Additional file 1: Figure S1).Figure 1 Representative production of clinical grade NY-ESO-1 specif
with CD8 and Tetramer staining of untreated PBMC from patient 1. B. Sma
after 2 stimulations using peptide pulsed dendritic cells. C. The 3 positive w
expansions. CD8 and tetramer staining of the final product is shown. D. Th
endogenously NY-ESO-1 expressing tumor line (NY-ESO-1). Mel 526 is an HThe flow sorted NY-ESO-1-specific T cells were then
stimulated with anti CD3 mAb in T25 flasks, which
yielded an average of 197 × 106 (range 73 to 331 × 106) T
cells after 14 days. Larger volume expansions were then
performed in either GREX containers or cell culture bags
in the CPF. For two of the patients (#4 and #6), we per-
formed the large volume expansion on T cells sorted from
only a fraction of the positive wells. The average bag or
GREX REP produced a 1204-fold expansion (range 650-
1754 fold). All cell products were expanded to over 2 ×
1010 cells, and except for patient #5, the final cell product
was >85% CD8+ and NY-ESO-1 tet+ (range 67.2-97.1%)
(Table 2 and Additional file 1: Figure S2). Based on
these percentages, the absolute number of antigen specificic T cell products from patient 1. A. No detectable cells are observed
ll CD8+ and Tetramer+ were observed in 3 wells of three 48 well plates
ells were sorted using the clinical grade cell sorted and underwent 2
e final product was able to lyse peptide pulsed targets as well as an
LA-A2+, NY-ESO-1− tumor line used as a control.




























Patient 1 3 3 0.62% 8.05% 3.39% 3 230 Bag 33 57.9
Patient 2 1 5 0.57% 1.90% 1.00% 5 73 GREX 68 44.2
Patient 3 1 7 0.01% 5.23% 1.23% 7 224 GREX 25 26.4
Patient 4 2 6 0.11% 3.68% 1.03% 4 157 GREX 19 20.7
Patient 5 2 3 0.07% 1.55% 0.57% 3 331 GREX 32
Patient 6 2 5 0.11% 7.24% 2.80% 1 169 Bag 18 24.6
Mean 1.8 4.8 0.2% 4.6% 1.7% 3.8 197.3 32.4 34.8
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54.7 × 109. Cell doses in prior studies performed by our
program that have led to clinical responses used 1010
cells/m2, suggesting this strategy for isolating and expand-
ing NY-ESO-1 specific T cells can yield therapeutically
relevant cell doses.
Phenotype and function of NY-ESO-1-specific CD8+ T cells
Exposure to IL-21 during in vitro priming has previously
been shown to enrich for a population of CD8+ T cells
with high affinity recognition of tumor antigen, effector
function, and expression of co-stimulatory molecules
such as CD28 [18,19]. Phenotype analysis of the final ex-
panded NY-ESO-1 specific T cell products demonstrated
expression of CD45RO, CD27 and CD28 on the majority
of CD8+ T cells, and the absence of CCR7 or CD62L, con-
sistent with an effector memory like phenotype. In almost
all cases, a subpopulation of CD127hi also appears in the
final T cell product also suggesting a memory-like pheno-
type (see Additional file 1: Figure S3).
We evaluated the function of the NY-ESO-1-specific T
cell products by assaying specific lysis of T2 (HLA-A2+)
targets pulsed with titrated concentrations of NY-ESO-1
peptide as well as the NY-ESO-1+ tumor cell line Mel
A375. All cell products exhibited specific lysis of T2 cells
pulsed with <0.01 μg/ml of NY-ESO-1 peptide and of
the Mel A375 tumor cells that endogenously expressed
NY-ESO-1 (Figure 2A). The lytic ability of NY-ESO-1
specific CTL generated from the sarcoma patients in this
study was comparable to a high affinity NY-ESO-1-spe-
cific T cell clones that we previously isolated [23], and to
T cells transduced with the high affinity mutant αLY NY-
ESO-1 specific TCR and sorted to >80% purity (Figure 2A
and B). In response to T2 cells pulsed with NY-ESO-1
peptide, the T cell products from all patients secreted
IFN-γ (mean 305 pg/mL, range 143 to 425 pg/mL) and
TNF alpha (mean 674.9 pg/mL, range 313.4 to 1113.9 pg/
mL) (Additional file 1: Figure S4). In each case, the NY-
ESO-1 specific CTL lines were also confirmed to lyse a SS
tumor line (SYO-1) and a MRCL tumor line (402) whichhad been transfected with the gene for A*0201 (Additional
file 1: Figure S5).
Thus, the avidity and effector function of antigen-
specific CTL derived from the peripheral blood is sufficient
to recognize endogenous tumor associated antigens and
compares favorably to a clinically relevant high affinity mu-
tant TCR. In order to confirm that NY-ESO-1 specific cells
could be generated in patients without NY-ESO-1 express-
ing tumors, we also made cells through this process in two
healthy donors which were also able to recognize peptide
pulsed T2’s and endogenously expressed peptide.
Clonality of products
We next assessed the clonality of the T cell products using
TCR Vβ spectratyping. All products were oligoclonal with
a range of high intensity peaks from 2 (patient #2) to 15
(patient #4) (Additional file 1: Figure S6). In order to bet-
ter quantify the TCR composition of these products, deep
sequencing of the TCR was performed on patient #1 and
patient #4 (Adaptive Biotechnologies). Despite the fact
that the cell product from patient #1 was comprised of
tetramer positive T cells sorted and expanded from 3 indi-
vidual 48 wells, the final cell product was almost entirely
comprised of a single dominant clone constituting 86.3%
of the TCR sequence reads. The next 5 most common se-
quences comprised 7.3% of the total sequences observed.
A total of 235 were observed in the infusion product
(Additional file 1: Figure S7). The product from patient #4
combined 4 wells and also contained a dominant clone
(85.4% of the sequences). The next most common 6
clones comprised 9.05% of the product and a total of 435
sequences were observed. In composite, our data demon-
strates the feasibility and reproducibility of generating a
single clone dominant but still oligoclonal, tumor-reactive,
NY-ESO-1 specific CD8+ -T cells from sarcoma patients
using clinical cell sorting technology.
Discussion
In light of the significant clinical responses observed
among patients receiving antigen-specific T cells recognizing
Figure 2 (See legend on next page.)
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Figure 2 Functional avidity of NY-ESO-1 specific T cells. A. NY-ESO-1 specific T cell products from patients #1-#6. The left panel for each
patient shows the lysis of T2 cells pulsed with various concentrations of NY-ESO-1 peptide by NY-ESO-1-specific T cells at an effector to target
(E:T) ratio of 20:1. The right panel shows lysis of the NY-ESO-1 expressing tumor cell line MelA375 at various E:T ratios. The tumor cell line Mel526
(NY-ESO-1 negative, gp100 positive) is a negative control. B. Lysis of NY-ESO-1 peptide pulsed T2 cells and tumor cells by a high affinity NY-ESO-1
T cell clone isolated by our lab, T cells transfected with the αLY TCR and sorted to >80% purity with NY-ESO-1 tetramer, and a gp100154-162
specific T cell clone.
Pollack et al. Journal for ImmunoTherapy of Cancer 2014, 2:36 Page 6 of 10
http://www.immunotherapyofcancer.org/content/2/1/36melanoma and leukemia-associated antigens, a means to
target more commonly expressed tumor-associated anti-
gens using a method that is relatively expedient and
clinically feasible would be desirable. To this end, we
developed a clinically-approved approach to isolate en-
dogenous antigen-specific T cells from the peripheral blood
for adoptive therapy (“endogenous T cell” or ETC therapy).
An unbiased source of T cells would be readily available
from the peripheral blood in contrast to TIL therapy
(where a surgically accessible tumor with an adequate
population of infiltrating lymphocytes is required), In con-
trast to engineered TCR or CAR, no genetic modification
is required and there is greater flexibility in targeting
tumor-associated antigens. With ETC therapy, more rapid
implementation of clinical studies is also possible since the
only requirement is a new GMP-grade peptide whereas
specific toxicities and binding properties associated with
each new TCR or CAR construct need to be addressed. To
demonstrate the feasibility of the form of ETC therapy pre-
sented in this study, we target a prototypic cancer testis
antigen (CT antigen), NY-ESO-1, expressed in several solid
tumor types including breast, colorectal, ovarian, lung can-
cer and sarcoma.
Patients with soft tissue sarcomas can express very high
levels of NY-ESO-1 but the often undetectable levels of
NY-ESO-1 specific CD8+ T cells in their peripheral blood
has made it difficult to generate autologous NY-ESO-1 T
cell products for adoptive immunotherapy. Here we dem-
onstrated that after stimulating CD25 depleted T cells from
sarcoma patients with autologous dendritic cells pulsed
with the NY-ESO-1157-165 peptide and in vitro exposure to
IL-21, rare wells containing measurable tetramer positive
T cells can be identified and clinical grade cell sorting can
be used to enrich and expand these populations to large
numbers of highly purified tumor-reactive T cells. The cell
products are oligoclonal, have an effector memory pheno-
type, and are of sufficient functional avidity to lyse T2 cells
pulsed with low concentrations of NY-ESO-1 peptide, and
tumor cell lines that express NY-ESO-1.
We were able to obtain regulatory approval from the
FDA to use this methodology for the generation of clin-
ical grade T cell products for the treatment of patients
with advanced cancer. The selection reagents for cell
sorting, peptide-MHC tetramer complexes conjugated to
a fluorescence molecule, were tested for sterility, endo-
toxin and mycoplasma prior to GMP use in order toassure safety in these reagents in a GMP environment.
While MHC streptamers (produced by IBA) offer the
advantage of reversible binding to the target cell [24,25],
there was no apparent impact on the ability to expand
these cells after sorting and given the small amount of
tetramer reagent used and the multiple washes occurring
during the two expansions, any remaining tetramer
present in the final product is unlikely to be clinically
relevant and was not a concern for regulatory approval.
Other investigators have used retroviral and lentiviral
vectors to insert an NY-ESO-1 specific TCR into T cells
and redirect their specificity to tumor cells [5,26]. Gen-
etic modification has the advantage of using an off the
shelf reagent to engineer each patient’s T cells with an
identical high affinity TCR. However, there are theoret-
ical safety concerns related to the potential for cross
pairing of the introduced TCR chains with endogenous
chains to confer autologous reactivity [11] and the use of
affinity-enhanced and xenogeneic TCR has also raised
serious safety concerns related to recent patient deaths
[8,27]. Practical considerations of genetically modifying
cells for altered specificity such as the cost and regulatory
burden are also significant issues for many labs. The ETC
(endogenous T cell therapy) approach presented here, ob-
viates many of these issues and can provide T cell prod-
ucts that have comparable avidity and function to those
generated by transfer of genes that encode a high affinity
NY-ESO-1 specific TCR.
For this study, IL-21 was used to enrich for a popula-
tion of CD8+ T cells with a central memory phenotype
[19] which in our previous studies has demonstrated
long-term in vivo persistence [28]. Our decision to set a
target cell dose of 1010 cells/m2 was based on prior stud-
ies where this dose range has been effective and allows
for in vivo tracking of transferred T cells [2,13,29]. In
light of the high replicative potential of IL-21 –primed
CTL, a lower optimal cell dose may yet be determined; a
lower dose requirement would allow for the collection of
lower blood volumes and increase the feasibility of gener-
ating T cells to multiple targets from a single collection.
It is interesting to speculate on why the two final
products tested by deep sequence were both over 85%
comprised of a dominant clone and all products con-
sisted of 15 or fewer clones. It may be that T cells spe-
cific for NY-ESO-1 are infrequently found in the natural
repertoire. It is also likely that certain clones become
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cell sorting.
This was a small series limited to HLA A*0201 posi-
tive patients with NY-ESO-1 expressing sarcomas, ac-
companied by some variability among the NY-ESO-1
specific T cell products with regards to their lytic ability
and expression of markers of T cell differentiation. How-
ever, clinical cell sorting with HLA tetramers offers a
platform that can be easily adapted to additional MHC
restricted targets (for example other CT antigens such as
PRAME and MAGE family antigens), and additional
HLA alleles. Moreover this approach may be used with
other reagents for detecting tumor-reactive T cells such
as CD137, where knowledge of the HLA restricting allele
and tumor antigen is not necessary [30]. Antigen-
specific CD4 T cells have also been shown to be effective
for the treatment of patients with solid tumor malignan-
cies and, with further development of the Class II tetra-
mers, it will be possible to rapidly isolate such T cells in
future trials [3,31,32].
In summary, the results of this study demonstrate that
rare tumor-reactive antigen-specific T cells can be suc-
cessfully isolated from the peripheral blood of patients
and expanded to numbers sufficient for adoptive ther-
apy. By the use of in vitro stimulation as a means to aug-
ment the population of antigen-specific CTL in culture
and enrich for a pool of CD28hi helper-independent
CD8+ T cells following exposure to IL-21, together with
tetramer-guided cell sorting under clinical manufactur-
ing conditions, it is feasible to generate tumor-reactive
antigen-specific CTL of sufficient magnitude (>30 bil-
lion) for therapy in 5-6 weeks from PBMC collection to
T cell product. Strategies to further streamline this ap-
proach and validate the routine generation of T cells
against additional target antigens such as WT-1, and
additional CT family antigens that are expressed broadly
in solid tumors, will facilitate entry of adoptive therapy
into mainstream clinical practice and consideration as a
possible treatment modality in patients with solid tumor
malignancies.
Conclusion
NY-ESO-1 specific T cells can be isolated and expanded
from the peripheral blood of patients with NY-ESO-1
expressing cancers under clinical manufacturing condi-
tions for use in adoptive T cell therapy trials.
Methods
Patients, sample acquisition and initial processing
Patients were enrolled on protocols approved by the
Fred Hutchinson Cancer Research Center (FHCRC) IRB
for tissue and blood procurement between September
2011 and May 2012, and provided informed consent in
accordance with the Helsinki Declaration. HLA typingof patient samples was performed at the Puget Sound
Blood Center (PSBC). Patients that expressed HLA
A*0201, had an ECOG performance status of 1 and tumor
biopsies with positive staining for NY-ESO-1 in >25% of
cells by immunohistochemistry underwent leukapheresis
at either the PSBC or University of Washington General
Clinical Research Center. All further processing of the leu-
kapheresis product was performed at FHCRC in the Cell
Professing Facility (CPF) under current Good Manufactur-
ing Practice (cGMP) guidelines. A portion of the leuka-
pheresis product (2 × 109 cells) was CD25 depleted on a
CliniMACS system using clinical grade CD25 MicroBeads
[Miltenyi Biotec, Auburn, CA, USA] to remove CD4+
regulatory cells. Both the CD25-depleted mononuclear cell
fraction, as well as the remaining unprocessed peripheral
blood mononuclear cells (PBMC), were cryopreserved; the
latter being used for dendritic cell (DC) generation.
Culture of dendritic cells
The protocols for DC generation have been described previ-
ously [33]. Briefly, PBMC were suspended in AIM-V
medium at 3 × 10^6 cells/mL, and then placed in sterile tis-
sue culture dishes at 3 mL/well to separate plastic adherent
and non-adherent populations by culture for 1 hour at 37°C.
Adherent cells were treated with GM-CSF (800 U/mL)
[MP Biomedicals, Santa Ana, CA, USA] and IL-4 (500 U/
mL) [R&D Systems, Minneapolis, MN, USA] for 6 days to
promote DC differentiation, and the DC were then ma-
tured for 2 days using a cytokine cocktail containing TNF-
α (10 ng/mL), IL-1β (2 ng/mL), IL-6 (1000 U/mL), PGE-2
(1000 ng/mL) [all from R&D Systems, Minneapolis, MN,
USA], IL-4 (500 U/mL) and GM-CSF (800 U/mL). Mature
DC’s were generally used fresh (without freezing or thaw-
ing) for the initial stimulation but excess DC’s were frozen
and frequently used in the second stimulation.
Stimulation of NY-ESO-1 specific T cells
DC’s were pulsed for 2 hours with 10-40 μg/mL of the
NY-ESO-1157-165 peptide in PBS with 1% HSA, washed, ir-
radiated (5000 rads), and then co-cultured in 48 well plates
with CD25 depleted PBMC in RPMI, 25 mM HEPES, 2
mM L-glutamine, 10% human AB serum (CTL medium)
and β2-microglobulin (3 μg/mL) [Scripps Laboratories,
San Diego, CA, USA]. Each plate was seeded with 70 × 106
CD25 depleted PBMC and 1.8 to 5 × 106 DC's divided
equally among the 48 wells. Two stimulations with peptide
pulsed DC were performed 7 days apart. During the first
stimulation, IL-21 (30 ng/mL) [Peprotech, Rocky Hill, NJ,
USA] was added twice in the first 4 days, and during the
second stimulation cycle, IL-21 (30 ng/mL) is added on
the first day and IL-2 (10 ng/mL) [Bayer, Terrytown, NY,
USA] and IL-7 (5 ng/mL) [R&D Systems, Minneapolis,
MN, USA] were added on the first day and days two
through four [18]. Stimulations for gp100 specific and
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protocol using gp100154-162 or MART127-35 peptides,
respectively.
Sorting and expansion
After two stimulations, an aliquot of each well was
stained with an HLA A*0201 MHC tetramer folded with
the NY-ESO-1157-165 peptide produced in the Immuno-
logic Monitoring Core Facility at FHCRC. Wells that
contained >0.5% tetramer positive cells were pooled,
sorted using only forward, side scatter and single color
tetramer parameters on a clinically qualified INFLUX
cell sorter [Becton Dickenson, Franklin Lakes, NJ, USA]
located within the CPF, and expanded using a rapid ex-
pansion protocol (REP) in a sterile 25 mL flask using an
IL-2 concentration of 50U/mL as previously described
[34]. In some cases, wells with <0.5% tetramer positive
cells were sorted and expanded if there was clearly a dis-
tinct tetramer positive population. After expansion, a
sample of the T cells were again stained with anti-CD8
mAb and NY-ESO-1157-165 tetramer to determine the
degree of enrichment of tetramer positive (tet+) cells,
and tested in a chromium release assay for lysis of T2
lymphocytes pulsed with NY-ESO-1157-165 peptide. A
final large volume expansion was performed using either
bags [Lifecell, Branchburg, NJ, USA] or GREX flasks
[Wilson-Wolf, St. Paul, MN, USA].
To facilitate detailed functional analysis, an aliquot of
some T cell products was removed from the CPF after
the first expansion, and expanded in the research lab for
in vitro assays to assess recognition of target cells pulsed
with various concentrations of peptide and to assess
cytokine production in response to antigen stimulation.
Cell surface phenotype and TCR Vβ spectratyping were
performed on aliquots from the second expansion.
Phenotyping and functional analysis of NY-ESO-1-specific
T cells
Cell surface phenotype was determined by co-staining with
NY-ESO-1 tetramer (APC) and the following fluorochrome
conjugated antibodies: CD8 (BV421) [BD Bioscience,
Franklin Lakes, NJ, USA], CD28 (PE- Texas Red) [Beck-
man Coulter, Brea Ca, USA], CD27 (BV711), CCR7 (PE-
Cy7), CD127 (PE) [all BD Pharmigen, San Diego, CA,
USA], CD62L (APC-eFluor780) [Biolegend, San Diego,
CA, USA], and CD45RO (FITC) [Invitrogen, Grand Island,
NY]. Cells were analyzed on an LSRII [Becton Dickinson,
Franklin Lakes, NJ, USA] using FlowJo software.
The NY-ESO-1 specificity of the expanded T cell prod-
ucts was confirmed using chromium release assay per-
formed on day 12 of the REP. T2 lymphocytes cultured
alone for 2 hours or in media with the NY-ESO-1157-165
peptide and HLA A*0201 positive, NY-ESO-1 positive
tumor line Mel A375 (A375) were used as target cells.In order to test NY-ESO-1 specific CTL lines in sar-
coma tumor lines, the SS cell line SYO-1 (gift of Dr.
Akira Kawai [35]) and the MRCL cell line 402 (gift of
Pierre Aman [36] ) were used. Because neither of these
cell lines are positive for HLA A*0201, they were trans-
fected with the lentivirus pRRLSIN with A*0201 cloned
into it. To further purify the A*0201 expressing popula-
tion, tumor cells were stained using an antibody for A02
(PE) [BD Pharmigen, San Diego, CA, USA] then sorted
using a FACSAria cell sorter (Becton Dickson) to isolate
A02 expressing tumor cells. Cell were then grown in cul-
ture and confirmed to express A02 by flow cytometry
prior to chromium release assay.
Target cells were labeled with 100 μCi 51Cr in 1 mL of
media and co-cultured with effector T cells for 4-6 hours
at 37°C plus 5% CO2 at a 20:1 effector to target (E:T) ra-
tio unless otherwise specified. Chromium release experi-
ments were performed in sextuplicate and to remove
outliers in a consistent fashion, the highest and lowest
values for each target/effector ratio were discarded. As a
positive control, we tested an NY-ESO-1-specific T cell
clone generated in our lab [23], and T cells transduced
with the αLY NY-ESO-1 specific TCR [26] (gift of Paul
Robbins courtesy of Dr. E.H. Warren).
For cytokine analysis, T cells were incubated overnight
at a 20:1 E:T ratio (200,000 effectors with 10,000 targets)
in 200 μL CTL media with T2 lymphocytes alone or with
T2 lymphocytes pulsed with NY-ESO-1157-165 peptide
(10 μg/mL) for 2 hours and then washed before plating
in the assay. Supernatant was analyzed for using a lumi-
nex assay for IFN-gamma (Fisher) and TNF alpha [R&D
Systems, Minneapolis, MN, USA].
Immunohistochemistry
Immunohistochemical staining for all SS and MRCL pa-
tients was performed at the University of Washington
Pathology lab with mAb specific for NY-ESO-1 (1:100,
E978 clone, Life Technologies, Grand Island, NY) using
an automated immunostainer (Bond III). Testis was used
as a positive control.
Spectratyping and deep sequencing of T cell receptors
TCR β-chain spectratype analysis was performed by the
Immune Monitoring Laboratory at Fred Hutchinson
Cancer Research Center according to the protocol devel-
oped by Akatsuka et al. [37] Briefly, cDNA was generated
from 1-5 × 106 cells and five multiplex PCR reactions were
run to amplify the CDR3 variable regions of each of the
23 TCR β-chain families. The PCR products were ana-
lyzed by capillary electrophoresis on the 3730 xl DNA
analyzer and GeneMapper software [Life Technologies/
Applied Biosystems, Van Allen Way, Ca, USA]. TCR Vβ
sequencing and normalization was performed by Adaptive
Biotechnologies [Seattle, WA, USA].
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Additional file 1: Figure S1. Results after 2 stimulations of PBMC from
a melanoma patient using DC’s pulsed with the MART-127-35 peptide.
Figure S2. CD8 and NY-ESO-1 Tetramer staining of fully expanded,
clinical grade products. Figure S3. Expression of markers of memory
phenotype CD45RO, CD27, CD28, CD62L, CCR7, and CD127 (blue) and
controls (red). Figure S4. IFN gamma and TNF alpha of fully expanded
clinical grade products following co-culture with peptide pulsed and
un-pulsed T2 lymphocytes. Figure S5. Chromium release assay
demonstrating specific lysis of the SS tumor line SYO-1 and the MRCL
tumor line 402 at a 20:1 effector to target ratio. Because these tumor lines
do not express the HLA A*0201, they were transfected with a lentivirus
encoding for A*0201, purified for the A02 expressing cells by flow sorting
and grown in culture prior to this assay. Figure S6. Vβ spectratyping of
each fully expanded clinical products. Figure S7. T cell products are
oligoclonal.
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